<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2019-4-169-184</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-2570</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Патофизиологические механизмы, лежащие в основе антипсихотик-индуцированной тардивной дискинезии</article-title><trans-title-group xml:lang="en"><trans-title>Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6836-9590</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вайман</surname><given-names>Е. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Vayman</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-невролог, ординатор,</p><p>192019, г. Санкт-Петербург, ул. Бехтерева, 3 </p></bio><bio xml:lang="en"><p>Neurologist, Resident,</p><p>3, Bekhterev Str., St.-Petersburg, 192019</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2840-837X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шнайдер</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shnayder</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, вед. науч. сотрудник, отделение персонализированной психиатрии и неврологии, </p><p>192019, г. Санкт-Петербург, ул. Бехтерева, 3 </p></bio><bio xml:lang="en"><p>DM, Professor, Leading Researcher, Department of Personalized Psychiatry and Neurology, </p><p>3, Bekhterev Str., St.-Petersburg, 192019</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5618-4206</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Незнанов</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Neznanov</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, науч. руководитель отделения гериатрической психиатрии, директор, </p><p>192019, г. Санкт-Петербург, ул. Бехтерева, 3 </p></bio><bio xml:lang="en"><p>DM, Professor, Scientific Director, of the Department of Geriatric Psychology, Director,</p><p>3, Bekhterev Str., St.-Petersburg, 192019</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1874-9434</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насырова</surname><given-names>Р. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasyrova</surname><given-names>R. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотрудник, руководитель отделения персонализированной психиатрии и неврологии,</p><p>192019, г. Санкт-Петербург, ул. Бехтерева, 3 </p></bio><bio xml:lang="en"><p>DM, General Researcher, Head of the Department of Personalized Psychiatry and Neurology,</p><p>3, Bekhterev Str., St.-Petersburg, 192019</p></bio><email xlink:type="simple">nreginaf77@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр (НМИЦ) психиатрии и неврологии им. В.М. Бехтерева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bekhterev National Medical Research Center (NMRC) of Psychiatry and Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>01</month><year>2020</year></pub-date><volume>18</volume><issue>4</issue><fpage>169</fpage><lpage>184</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф.</copyright-holder><copyright-holder xml:lang="en">Vayman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/2570">https://bulletin.ssmu.ru/jour/article/view/2570</self-uri><abstract><p>Цель – анализ результатов классических и современных исследований, отражающих патофизиологические механизмы антипсихотик-индуцированной тардивной дискинезии.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен поиск полнотекстовых публикаций на русском и английском языках за последнее десятилетие в базах данных еLibrary, PubMed, Web of Science, Springer, используя ключевые слова «тардивная дискинезия» (ТД), «лекарственно-индуцированная тардивная дискинезия», «антипсихотики» (АП), «нейролептики», «типичные антипсихотики», «атипичные антипсихотики», «патофизиология», «этиология» и комбинированные поиски слов. Кроме того, в лекцию включены более ранние публикации, имеющие исторический интерес.</p></sec><sec><title>Результаты</title><p>Результаты. В лекции предложены теории развития АП-индуцированной ТД, рассматривающие влияние на дофаминергические рецепторы, дофаминергические нейроны, на нейроны базальных ганглий, и прочие теории: активация эстрогеновых рецепторов, нарушение обмена мелатонина, нарушение эндогенной опиоидной системы, оксидативный стресс с преобладанием процессов окисления, блокада 5-НТ2 -рецепторов, снижение уровня пиридоксина, генетическая предрасположенность, взаимодействие АП с церебральным микроэлементом – железом, карбониловый стресс и имунновоспаление, роль нейротрофического фактора.</p></sec><sec><title>Заключение</title><p>Заключение. Раскрытие механизмов АП-индуцированной ТД даст ключ к разработке стратегии персонализированной профилактики и терапии рассматриваемого неврологического осложнения АП-терапии шизофрении в реальной клинической практике.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. To analyze the results of classical and modern studies reflecting the pathophysiological mechanisms of antipsychotic-induced tardive dyskinesia.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We searched for full-text publications in Russian and English in the databases of E-Library, PubMed, Web of Science and Springer published over the past decade, using keywords (tardive dyskinesia (TD), drug-induced tardive dyskinesia, antipsychotics (AP), neuroleptics, typical antipsychotics, atypical antipsychotics, pathophysiology, etiology and combinations of these words). In addition, the review included earlier publications of historical interest.</p></sec><sec><title>Results</title><p>Results. The lecture proposed theories of development of AP-induced TD, examining its effect on dopaminergic receptors, dopaminergic neurons, neurons of the basal ganglia, and other theories: activation of estrogen receptors, disorders of melatonin metabolism, disorders of the endogenous opioid system, oxidative stress with predominant oxidation processes, blockade of 5-HT2-receptors, a decrease in the pyridoxine level, genetic predisposition, interaction of AP with the brain trace element – iron, carbonyl stress and immune inflammation and the role of the neurotrophic factor.</p></sec><sec><title>Conclusion</title><p>Conclusion. The disclosure of the mechanisms of AP-induced TD will allow the development of a strategy for personalized prevention and therapy of the considered neurological complication of the AP-therapy for schizophrenia in real clinical practice. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>тардивная дискинезия</kwd><kwd>лекарственно-индуцированная тардивная дискинезия</kwd><kwd>антипсихотики</kwd><kwd>теории</kwd><kwd>патофизиология</kwd><kwd>патогенез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tardive dyskinesia</kwd><kwd>drug-induced tardive dyskinesia</kwd><kwd>theories</kwd><kwd>antipsychotics</kwd><kwd>pathophysiology</kwd><kwd>pathogenesis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publ., 2013.</mixed-citation><mixed-citation xml:lang="en">Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publ., 2013.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cornett E.M., Novitch M., Kaye A.D., Kata V., Kaye A.M. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017; 17 (2): 162–174. PubMed PMID: 28638290 DOI: 10.1043/TOJ-16-0108.</mixed-citation><mixed-citation xml:lang="en">Cornett E.M., Novitch M., Kaye A.D., Kata V., Kaye A.M. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017; 17 (2): 162–174. PubMed PMID: 28638290 DOI: 10.1043/TOJ-16-0108.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Хубларова Л.А., Захаров Д.В., Михайлов В.А. Стратификация риска развития поздних лекарственно-индуцированных осложнений. Обозрение психиатрии и неврологии им. В.М. Бехтерева. 2017; 4: 111–114.</mixed-citation><mixed-citation xml:lang="en">Khublarova L.A., Zakharov D.V., Mikhaylov V.A. Stratification of the risk of developing tardive drug-induced complications. Review of Psychiatry and Neurology. 2017; 4: 111–114 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Хубларова Л.А., Захаров Д.В., Михайлов В.А., Фурсова И.В. Динамика показателей качества жизни пациентов с поздними нейролептическими дискинезиями в процессе ботулинотерапии. Обозрение психиатрии и неврологии им. В.М. Бехтерева. 2016; 4: 86–91.</mixed-citation><mixed-citation xml:lang="en">Khublarova L.A., Zakharov D.V., Mikhaylov V.A. Dynamics of quality of life indicators in patients with tardive neuroleptic dyskinesias in the process of botulinum therapy. Review of Psychiatry and Neurology. 2016; 4; 86–91 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Корнетова Е.Г., Семке А.В., Дмитриева Е.Г., Бородюк Ю.Н., Бойко А.С. Клинические и социальные факторы риска тардивной дискинезии у пациентов с шизофренией в процессе лечения антипсихотиками. Бюллетень сибирской медицины. 2015; 14 (1): 32–39. DOI: 10.20538/1682-0363-2015-1-32-39.</mixed-citation><mixed-citation xml:lang="en">Kornetova E.G., Semke A.V., Dmitrieva E.G., Borodyuk Yu.N., Boyko A.S. Clinical and social risk factors of tardive dyskinesia in patients with schizophrenia during antipsychotic treatment. Bulletin of Siberian Medicine. 2015; 14 (1): 32–39 (in Russ.). DOI: 10.20538/1682-0363-2015-1-32-39.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ellison G., Johansson P., Levin E., See R., Gunne L. Chronic neuroleptics alter the effects of the D1 agonist SK&amp;F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology. 1988; 96 (2): 253–257.</mixed-citation><mixed-citation xml:lang="en">Ellison G., Johansson P., Levin E., See R., Gunne L. Chronic neuroleptics alter the effects of the D1 agonist SK&amp;F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology. 1988; 96 (2): 253–257.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci. 1983; 33 (25): 2479–2482.</mixed-citation><mixed-citation xml:lang="en">Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci. 1983; 33 (25): 2479–2482.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rosengarten H., Schweitzer J.W., Friedhoff A.J. The effect of novel antipsychotics in rat oral dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiat. 1999; 23 (8):</mixed-citation><mixed-citation xml:lang="en">Rosengarten H., Schweitzer J.W., Friedhoff A.J. The effect of novel antipsychotics in rat oral dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiat. 1999; 23 (8):</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">–1404.</mixed-citation><mixed-citation xml:lang="en">–1404.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol. J. Pharmacol. 2002; 54 (2): 299–312.</mixed-citation><mixed-citation xml:lang="en">Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol. J. Pharmacol. 2002; 54 (2): 299–312.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Takano A., Suhara T., Kusumi I., Takahashi Y., Asai Y., Yasuno F., Ichimiya T., Inoue M., Sudo Y., Koyama T. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006; 30 (1): 75–81. PMID: 16040180.</mixed-citation><mixed-citation xml:lang="en">Takano A., Suhara T., Kusumi I., Takahashi Y., Asai Y., Yasuno F., Ichimiya T., Inoue M., Sudo Y., Koyama T. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006; 30 (1): 75–81. PMID: 16040180.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Amer. J. Psychiat. 1999; 156 (2): 286–293.</mixed-citation><mixed-citation xml:lang="en">Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Amer. J. Psychiat. 1999; 156 (2): 286–293.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kasper S., Tauscher J., Kьfferle B., Barnas C., HeЯelmann B., Asenbaum S., Podreka I., Brьcke T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol – a 123I-IBZM SPECT study. Psychopharmacology. 1998; 136 (4): 367–373.</mixed-citation><mixed-citation xml:lang="en">Kasper S., Tauscher J., Kьfferle B., Barnas C., HeЯelmann B., Asenbaum S., Podreka I., Brьcke T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol – a 123I-IBZM SPECT study. Psychopharmacology. 1998; 136 (4): 367–373.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Farde L., Nordstrцm A.-L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D and D dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiat. 1992; 49 (7): 538–544.</mixed-citation><mixed-citation xml:lang="en">Farde L., Nordstrцm A.-L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D and D dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiat. 1992; 49 (7): 538–544.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Boyson S.J., McGonigle P., Luthin G.R., Wolfe B.B., Molinoff P.B. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 1988; 244 (3): 987–993. PMID: 2908050.</mixed-citation><mixed-citation xml:lang="en">Boyson S.J., McGonigle P., Luthin G.R., Wolfe B.B., Molinoff P.B. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 1988; 244 (3): 987–993. PMID: 2908050.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sanyal S., van Tol H.H. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J. Psychiatr. Res. 1997; 31 (2): 219–232. PubMed PMID: 9278187.</mixed-citation><mixed-citation xml:lang="en">Sanyal S., van Tol H.H. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J. Psychiatr. Res. 1997; 31 (2): 219–232. PubMed PMID: 9278187.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry. 2002; 47 (1): 27–38. PMID: 11873706.</mixed-citation><mixed-citation xml:lang="en">Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry. 2002; 47 (1): 27–38. PMID: 11873706.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Weiner W.J. Drug-induced movement disorders. Encyclopedia of movement disorders. Academic Press, 2010: 340–347. DOI: 10.1016/b978-0-12-374105-9.00021-6.</mixed-citation><mixed-citation xml:lang="en">Weiner W.J. Drug-induced movement disorders. Encyclopedia of movement disorders. Academic Press, 2010: 340–347. DOI: 10.1016/b978-0-12-374105-9.00021-6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 1993; 34 (10): 713–738. PMID: 7904833.</mixed-citation><mixed-citation xml:lang="en">Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 1993; 34 (10): 713–738. PMID: 7904833.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmacol. 1991; 14 (6): 562–565. PMID: 1837757.</mixed-citation><mixed-citation xml:lang="en">De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmacol. 1991; 14 (6): 562–565. PMID: 1837757.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Moghaddam B., Bunney B.S. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 1993; 14 (3): 195–200.</mixed-citation><mixed-citation xml:lang="en">Moghaddam B., Bunney B.S. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 1993; 14 (3): 195–200.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 1994; 14 (7): 4159–4166.</mixed-citation><mixed-citation xml:lang="en">Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 1994; 14 (7): 4159–4166.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988; 451: 205–212.</mixed-citation><mixed-citation xml:lang="en">Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988; 451: 205–212.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993; 16 (14): 125–131.</mixed-citation><mixed-citation xml:lang="en">Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993; 16 (14): 125–131.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 2000; 61 (5): 525–541. PubMed PMID: 10748322.</mixed-citation><mixed-citation xml:lang="en">Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 2000; 61 (5): 525–541. PubMed PMID: 10748322.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Loonen A.J., Ivanova S.A. New insights into the mechanism of drug-induced dyskinesia. CNS Spectrums. 2013; 18 (1): 15–20.</mixed-citation><mixed-citation xml:lang="en">Loonen A.J., Ivanova S.A. New insights into the mechanism of drug-induced dyskinesia. CNS Spectrums. 2013; 18 (1): 15–20.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanova S.A., Loonen A.J., Pechlivanoglou P., Freidin M.B., Al Hadithy A.F., Rudikov E.V., Zhukova I.A., Govorin N.V., Sorokina V.A., Fedorenko O.Y., Alifirova V.M., Semke A.V., Brouwers J.R., Wilffert B. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl. Psychiatry. 2012; 2: e67. DOI: 10.1038/tp.2011.66.</mixed-citation><mixed-citation xml:lang="en">Ivanova S.A., Loonen A.J., Pechlivanoglou P., Freidin M.B., Al Hadithy A.F., Rudikov E.V., Zhukova I.A., Govorin N.V., Sorokina V.A., Fedorenko O.Y., Alifirova V.M., Semke A.V., Brouwers J.R., Wilffert B. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl. Psychiatry. 2012; 2: e67. DOI: 10.1038/tp.2011.66.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ando K. Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals. J. Toxicol. Sci. 1996; 21 (1): 105–107. PMID: 8852296.</mixed-citation><mixed-citation xml:lang="en">Ando K. Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals. J. Toxicol. Sci. 1996; 21 (1): 105–107. PMID: 8852296.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Klawans H.L., Rubowitz R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry. 1974; 37 (8): 941–947.</mixed-citation><mixed-citation xml:lang="en">Klawans H.L., Rubowitz R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry. 1974; 37 (8): 941–947.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Gerlach J., Reisby N., Randrup A. Doparninergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974; 34 (1): 21–35.</mixed-citation><mixed-citation xml:lang="en">Gerlach J., Reisby N., Randrup A. Doparninergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974; 34 (1): 21–35.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tarsy D., Leopold N., Sax D.S. Physostigmine in choreiform movement disorders. Neurology. 1974; 24 (1): 28–33. PMID: 4358998.</mixed-citation><mixed-citation xml:lang="en">Tarsy D., Leopold N., Sax D.S. Physostigmine in choreiform movement disorders. Neurology. 1974; 24 (1): 28–33. PMID: 4358998.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Di Figlia M. Synaptic organization of cholinergic neurons in the monkey striatum. J. Comp. Neurol. 1987; 255 (2): 245–258.</mixed-citation><mixed-citation xml:lang="en">Di Figlia M. Synaptic organization of cholinergic neurons in the monkey striatum. J. Comp. Neurol. 1987; 255 (2): 245–258.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gunne L.M., Bachus S.E., Gale K. Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias. Exp. Neurol. 1988; 100 (3): 459–469. PMID: 2835254.</mixed-citation><mixed-citation xml:lang="en">Gunne L.M., Bachus S.E., Gale K. Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias. Exp. Neurol. 1988; 100 (3): 459–469. PMID: 2835254.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tepper J.M., Lee C.R. GABAergic control of substantia nigra dopaminergic neurons. Prog. Brain Res. 2007; 160: 189–208. PMID: 17499115.</mixed-citation><mixed-citation xml:lang="en">Tepper J.M., Lee C.R. GABAergic control of substantia nigra dopaminergic neurons. Prog. Brain Res. 2007; 160: 189–208. PMID: 17499115.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochern. 1998; 71 (3): 1002–1012.</mixed-citation><mixed-citation xml:lang="en">Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochern. 1998; 71 (3): 1002–1012.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 1996; 66 (5): 1836–1844.</mixed-citation><mixed-citation xml:lang="en">Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 1996; 66 (5): 1836–1844.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Glazer W.M., Moore D.C., Bowers M.B., Brown W.A. Serum prolactin and tardive dyskinesia. Am. J. Psychiatry. 1981; 138 (11): 1493–1496.</mixed-citation><mixed-citation xml:lang="en">Glazer W.M., Moore D.C., Bowers M.B., Brown W.A. Serum prolactin and tardive dyskinesia. Am. J. Psychiatry. 1981; 138 (11): 1493–1496.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Turrone P., Seeman M.V., Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can. J. Psychiatry. 2000; 45 (3): 288–290. PMID:10779888.</mixed-citation><mixed-citation xml:lang="en">Turrone P., Seeman M.V., Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can. J. Psychiatry. 2000; 45 (3): 288–290. PMID:10779888.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Sandyk R., Kay S.R., Gillman M.A. The role of melatonin in the antipsychotic and motor-side effects of neuroleptics: a hypothesis. Int. J. Neurosci. 1992; 64 (1–4): 203–207. PMID: 1364141.</mixed-citation><mixed-citation xml:lang="en">Sandyk R., Kay S.R., Gillman M.A. The role of melatonin in the antipsychotic and motor-side effects of neuroleptics: a hypothesis. Int. J. Neurosci. 1992; 64 (1–4): 203–207. PMID: 1364141.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Idzikowski C., Mills F.J., Glennard R. 5-hydroxytrytamine-2-antagonist increases human slow wave sleep. Brain Research. 1986; 378 (1): 164–168.</mixed-citation><mixed-citation xml:lang="en">Idzikowski C., Mills F.J., Glennard R. 5-hydroxytrytamine-2-antagonist increases human slow wave sleep. Brain Research. 1986; 378 (1): 164–168.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Buckholtz N.S., Zhou D., Freedman D.X., Potter W.Z. Lysergic acid diethylamine (LSD) administration selectively downregulates serotonin, receptors in rat brain. Neuropsychopharmacology. 1990; 3 (2): 137–148.</mixed-citation><mixed-citation xml:lang="en">Buckholtz N.S., Zhou D., Freedman D.X., Potter W.Z. Lysergic acid diethylamine (LSD) administration selectively downregulates serotonin, receptors in rat brain. Neuropsychopharmacology. 1990; 3 (2): 137–148.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Miles A., Philbrick D.R.S. Melatonin and psychiatry. Biological Psychiatry. 1988; 23 (4): 405–425.</mixed-citation><mixed-citation xml:lang="en">Miles A., Philbrick D.R.S. Melatonin and psychiatry. Biological Psychiatry. 1988; 23 (4): 405–425.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffori O., Geffard M., van Ree J.M. Des-Tyr1-gamma-endorphin and haloperidol increase pineal gland melatonin levels in rats. Peprides. 1983; 4: 393–395.</mixed-citation><mixed-citation xml:lang="en">Gaffori O., Geffard M., van Ree J.M. Des-Tyr1-gamma-endorphin and haloperidol increase pineal gland melatonin levels in rats. Peprides. 1983; 4: 393–395.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Smith J.A., Mee T.J.X., Barnes J.D. Increased serum melatonin levels in chlorpromazine-treated psychiatric patients. Journal of Neural Transmission. 1978; 13: 397.</mixed-citation><mixed-citation xml:lang="en">Smith J.A., Mee T.J.X., Barnes J.D. Increased serum melatonin levels in chlorpromazine-treated psychiatric patients. Journal of Neural Transmission. 1978; 13: 397.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Stoessl A.J., Polanski E., Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov. Disord. 1993; 8 (4): 445–452. PMID: 7901759.</mixed-citation><mixed-citation xml:lang="en">Stoessl A.J., Polanski E., Frydryszak H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov. Disord. 1993; 8 (4): 445–452. PMID: 7901759.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNSDrugs. 2001; 15 (4): 287–310. PMID: 11463134.</mixed-citation><mixed-citation xml:lang="en">Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNSDrugs. 2001; 15 (4): 287–310. PMID: 11463134.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Cadet J.L., Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 1994; 18 (4): 457–467. PMID: 7708360.</mixed-citation><mixed-citation xml:lang="en">Cadet J.L., Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 1994; 18 (4): 457–467. PMID: 7708360.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Arai M., Miyashita M., Kobori A., Toriumi K., Horiuchi Y., Itokawa M. Carbonyl stress and schizophrenia. Psychiatry Clin. Neurosci. 2014; 68 (9): 655–665. DOI: 10.1111/pcn.12216.</mixed-citation><mixed-citation xml:lang="en">Arai M., Miyashita M., Kobori A., Toriumi K., Horiuchi Y., Itokawa M. Carbonyl stress and schizophrenia. Psychiatry Clin. Neurosci. 2014; 68 (9): 655–665. DOI: 10.1111/pcn.12216.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Itokawa M., Miyashita M., Arai M., Dan T., Takahashi K., Tokunaga T., Ishimoto K., Toriumi K., Ichikawa T., Horiuchi Y., Kobori A., Usami S., Yoshikawa T., Amano N., Washizuka S., Okazaki Y., Miyata T. Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin. Neurosci. 2018; 72 (1): 35–44. DOI: 10.1111/pcn.12613.</mixed-citation><mixed-citation xml:lang="en">Itokawa M., Miyashita M., Arai M., Dan T., Takahashi K., Tokunaga T., Ishimoto K., Toriumi K., Ichikawa T., Horiuchi Y., Kobori A., Usami S., Yoshikawa T., Amano N., Washizuka S., Okazaki Y., Miyata T. Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin. Neurosci. 2018; 72 (1): 35–44. DOI: 10.1111/pcn.12613.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Ohnuma T., Nishimon S., Takeda M., Sannohe T., Katsuta N., Arai H. Carbonyl stress and microinflammation-related molecules as potential biomarkers in schizophrenia. Front Psychiatry. 2018; 13: 9–82. DOI: 10.3389/fpsyt.2018.00082.</mixed-citation><mixed-citation xml:lang="en">Ohnuma T., Nishimon S., Takeda M., Sannohe T., Katsuta N., Arai H. Carbonyl stress and microinflammation-related molecules as potential biomarkers in schizophrenia. Front Psychiatry. 2018; 13: 9–82. DOI: 10.3389/fpsyt.2018.00082.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Arai M., Miyashita M., Ichikawa T., Itokawa M. Carbonyl stress-related schizophrenia – perspective on future therapy and hypotheses regarding pathophysiology of schizophrenia. Seishin Shinkeigaku Zasshi. 2012; 114 (3): 199–208 (in Japanese). PMID: 22568054.</mixed-citation><mixed-citation xml:lang="en">Arai M., Miyashita M., Ichikawa T., Itokawa M. Carbonyl stress-related schizophrenia – perspective on future therapy and hypotheses regarding pathophysiology of schizophrenia. Seishin Shinkeigaku Zasshi. 2012; 114 (3): 199–208 (in Japanese). PMID: 22568054.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Itokawa M., Arai M., Ichikawa T., Miyashita M., Okazaki Y. Studies on pathophysiology of schizophrenia with a rare variant as a clue. Brain Nerve. 2011; 63 (3): 223–231 (in Japanese). PMID: 21386123.</mixed-citation><mixed-citation xml:lang="en">Itokawa M., Arai M., Ichikawa T., Miyashita M., Okazaki Y. Studies on pathophysiology of schizophrenia with a rare variant as a clue. Brain Nerve. 2011; 63 (3): 223–231 (in Japanese). PMID: 21386123.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Voziyan P.A., Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol. Life Sci. 2005; 62 (15): 1671–1681. PMID: 15905958.</mixed-citation><mixed-citation xml:lang="en">Voziyan P.A., Hudson B.G. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol. Life Sci. 2005; 62 (15): 1671–1681. PMID: 15905958.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanova S.A., Geers L.M., Al Hadithy A.F., Pechlivanoglou P., Semke A.V., Vyalova N.M., Rudikov E.V., Fedorenko O.Y., Wilffert B., Bokhan N.A., Brouwers J.R., Loonen A.J. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2014; 50: 172–177. DOI: 10.1016/j.pnpbp.2013.12.015.</mixed-citation><mixed-citation xml:lang="en">Ivanova S.A., Geers L.M., Al Hadithy A.F., Pechlivanoglou P., Semke A.V., Vyalova N.M., Rudikov E.V., Fedorenko O.Y., Wilffert B., Bokhan N.A., Brouwers J.R., Loonen A.J. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2014; 50: 172–177. DOI: 10.1016/j.pnpbp.2013.12.015.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanova S.A., Toshchakova V.A., Filipenko M.L., Fedorenko O.Y., Boyarko E.G., Boiko A.S., Semke A.V., Bokhan N.A., Aftanas L.I., Loonen A.J. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World J. Biol. Psychiatry. 2015; 16 (3): 200–205. DOI: 10.3109/15622975.2014.995222.</mixed-citation><mixed-citation xml:lang="en">Ivanova S.A., Toshchakova V.A., Filipenko M.L., Fedorenko O.Y., Boyarko E.G., Boiko A.S., Semke A.V., Bokhan N.A., Aftanas L.I., Loonen A.J. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World J. Biol. Psychiatry. 2015; 16 (3): 200–205. DOI: 10.3109/15622975.2014.995222.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Fedorenko O.Y., Loonen A.J., Lang F., Toshchakova V.A., Boyarko E.G., Semke A.V., Bokhan N.A., Govorin N.V., Aftanas L.I., Ivanova S.A. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int. J. Neuropsychopharmacol. 2014; 18 (6): pii: pyu098. DOI: 10.1093/ijnp/pyu098.</mixed-citation><mixed-citation xml:lang="en">Fedorenko O.Y., Loonen A.J., Lang F., Toshchakova V.A., Boyarko E.G., Semke A.V., Bokhan N.A., Govorin N.V., Aftanas L.I., Ivanova S.A. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int. J. Neuropsychopharmacol. 2014; 18 (6): pii: pyu098. DOI: 10.1093/ijnp/pyu098.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanova S.A., Loonen A.J., Bakker P.R., Freidin M.B., Ter Woerds N.J., Al Hadithy A.F., Semke A.V., Fedorenko O.Y., Brouwers J.R., Bokhan N.A., van Os J., van Harten P.N., Wilffert B. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Med. 2016; 4: 2050312116643673. DOI: 10.1177/2050312116643673.</mixed-citation><mixed-citation xml:lang="en">Ivanova S.A., Loonen A.J., Bakker P.R., Freidin M.B., Ter Woerds N.J., Al Hadithy A.F., Semke A.V., Fedorenko O.Y., Brouwers J.R., Bokhan N.A., van Os J., van Harten P.N., Wilffert B. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Med. 2016; 4: 2050312116643673. DOI: 10.1177/2050312116643673.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Boiko A.S., Ivanova S.A., Pozhidaev I.V., Freidin M.B., Osmanova D.Z., Fedorenko O.Y., Semke A.V., Bokhan N.A., Wilffert B., Loonen A.J.M. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. World J. Biol. Psychiatry. 2019: 1–6. DOI: 10.1080/15622975.2018.1548780.</mixed-citation><mixed-citation xml:lang="en">Boiko A.S., Ivanova S.A., Pozhidaev I.V., Freidin M.B., Osmanova D.Z., Fedorenko O.Y., Semke A.V., Bokhan N.A., Wilffert B., Loonen A.J.M. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. World J. Biol. Psychiatry. 2019: 1–6. DOI: 10.1080/15622975.2018.1548780.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Calarge C.A., Murry D.J., Ziegler E.E., Arnold L.E. Serum ferritin, weight gain, disruptive behavior, and extrapyramidal symptoms in risperidone-treated youth. J. Child Adolesc. Psychopharmacol. 2016; 26 (5): 471–477. DOI: 10.1089/cap.2015.0194.</mixed-citation><mixed-citation xml:lang="en">Calarge C.A., Murry D.J., Ziegler E.E., Arnold L.E. Serum ferritin, weight gain, disruptive behavior, and extrapyramidal symptoms in risperidone-treated youth. J. Child Adolesc. Psychopharmacol. 2016; 26 (5): 471–477. DOI: 10.1089/cap.2015.0194.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Calarge C.A., Ziegler E.E., Del Castillo N., Aman M., McDougle C.J., Scahill L., McCracken J.T., Arnold L.E. J Iron homeostasis during risperidone treatment in children and adolescents. Clin. Psychiatry. 2015; 76 (11): 1500–1505.</mixed-citation><mixed-citation xml:lang="en">Calarge C.A., Ziegler E.E., Del Castillo N., Aman M., McDougle C.J., Scahill L., McCracken J.T., Arnold L.E. J Iron homeostasis during risperidone treatment in children and adolescents. Clin. Psychiatry. 2015; 76 (11): 1500–1505.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Calarge C.A., Ziegler E.E. Iron deficiency in pediatric patients in long-term risperidone treatment. J. Child Adolesc. Psychopharmacol. 2013; 23 (2): 101–109. DOI: 10.1089/cap.2012.0046.</mixed-citation><mixed-citation xml:lang="en">Calarge C.A., Ziegler E.E. Iron deficiency in pediatric patients in long-term risperidone treatment. J. Child Adolesc. Psychopharmacol. 2013; 23 (2): 101–109. DOI: 10.1089/cap.2012.0046.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Tan Y.L., Zhou D.F., Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2005; 74 (2–3): 263–270. PMID: 15722005.</mixed-citation><mixed-citation xml:lang="en">Tan Y.L., Zhou D.F., Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2005; 74 (2–3): 263–270. PMID: 15722005.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 1998; 155 (9): 1207–1213.</mixed-citation><mixed-citation xml:lang="en">Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry. 1998; 155 (9): 1207–1213.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">An H.M., Tan Y.L., Shi J., Wang Z.R., Soars J.C., Wu J.Q., Yang F.D., Huang X.F., Zhang X.Y. Altered IL2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr. Res. 2015; 162 (1–3): 261–268. DOI: 10.1016/j.schres.2014.12.037.</mixed-citation><mixed-citation xml:lang="en">An H.M., Tan Y.L., Shi J., Wang Z.R., Soars J.C., Wu J.Q., Yang F.D., Huang X.F., Zhang X.Y. Altered IL2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr. Res. 2015; 162 (1–3): 261–268. DOI: 10.1016/j.schres.2014.12.037.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Liu H., Kang Y., Liang J., Li C., Xiu M., Chen D., Yang F., Wang F., Wu G., Haile C.N., Kosten T.A., Kosten T.R., Zhang X.Y. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012; 198 (2): 329–331. DOI: 10.1016/j.psychres.2012.01.002. 65. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 1994; 90 (5): 311–315. PMID: 7872033.</mixed-citation><mixed-citation xml:lang="en">Liu H., Kang Y., Liang J., Li C., Xiu M., Chen D., Yang F., Wang F., Wu G., Haile C.N., Kosten T.A., Kosten T.R., Zhang X.Y. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012; 198 (2): 329–331. DOI: 10.1016/j.psychres.2012.01.002. 65. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 1994; 90 (5): 311–315. PMID: 7872033.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Вайман Е.Э., Толмачев М.Ю., Ахметова Л.Ш., Шнайдер Н.А., Насырова Р.Ф. Роль полиморфизма rs1800955 промотора гена DRD4 в развитии антипсихотик-индуцированных экстрапирамидных расстройств. Забайкальский медицинский вестник. 2019; 1: 14–24.</mixed-citation><mixed-citation xml:lang="en">Vayman E.E., Tolmachev M.Yu., Аkhmetova L.Sh., Shnayder N.А., Nasyrova R.F. The role of rs1800955 polymorphism of DRD4 gene promoter in development of antipsychoticinduced extrapyramidal disorders. The Transbaikalian Medical Bulletin. 2019; 1: 14–24 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Lanning R.K., Zai C.C., Mьller D.J. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016; 17 (12): 1339–1351. DOI: 10.2217/pgs.16.26.</mixed-citation><mixed-citation xml:lang="en">Lanning R.K., Zai C.C., Mьller D.J. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016; 17 (12): 1339–1351. DOI: 10.2217/pgs.16.26.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">De Leon J., Susce M.T., Pan R.M., Koch W.H., Wedlund P.J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J. Clin. Psychopharmacol. 2005; 25 (5): 448–456. PMID: 16160620.</mixed-citation><mixed-citation xml:lang="en">De Leon J., Susce M.T., Pan R.M., Koch W.H., Wedlund P.J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J. Clin. Psychopharmacol. 2005; 25 (5): 448–456. PMID: 16160620.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Ripke S., Neale B.M., Corvin A. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511 (7510): 421–427. DOI: 10.1038/nature13595.</mixed-citation><mixed-citation xml:lang="en">Ripke S., Neale B.M., Corvin A. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511 (7510): 421–427. DOI: 10.1038/nature13595.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
